China News Service, December 28. According to the website of the National Medical Insurance Administration, the National Medical Insurance Administration, in conjunction with the Ministry of Human Resources and Social Security and other departments, organized the adjustment of the 2020 National Medical Insurance Drug List.

In this adjustment, a total of 162 kinds of drugs were negotiated, 119 kinds of negotiations were successful, and the negotiation success rate was 73.46%.

The average price of successfully negotiated drugs was reduced by 50.64%.

In this adjustment, we attach great importance to the protection of drugs related to the treatment of new coronary pneumonia, and include ribavirin injection, Abidol granules and other drugs into the catalog. All drugs listed in the latest version of the national new coronary pneumonia diagnosis and treatment plan have been included in the national medical insurance Catalogue to help prevent and control the epidemic with practical actions.

  It is reported that the National Medical Security Administration, in conjunction with the Ministry of Human Resources and Social Security and other departments, organized the adjustment of the 2020 National Medical Insurance Drug List.

In accordance with the "Work Plan for the Adjustment of the National Medical Insurance Drug Catalogue in 2020", after enterprise declaration, expert review, standard calculation, on-site negotiation, etc., the list of drugs transferred into and out of the catalog has been determined, and the payment of some drugs in the catalog has been adjusted and formulated standard.

At present, this work has been successfully completed.

  In this adjustment, a total of 162 kinds of drugs were negotiated, 119 kinds of negotiations were successful, and the negotiation success rate was 73.46%.

The average price of successfully negotiated drugs was reduced by 50.64%.

  Through this catalogue adjustment, the total number of medicines in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" is 2,800, of which 1,426 are Western medicines and 1,374 are Chinese patent medicines.

There are still 892 kinds of Chinese herbal medicines in the catalog without adjustment.

  This catalogue adjustment has the following characteristics: First, adhere to the functional positioning of "guarantee basics" to ensure that the medical insurance fund expenditure is controllable.

In the process of catalogue adjustment, adhere to the basic principle of "do everything possible to ensure the basics, always adhere to the sustainability", do your best, do your best, firmly grasp the functional positioning of "basic protection", and negotiate through the transfer of drugs with low clinical value. Reduce the prices of drugs with significantly higher costs in the catalog and special negotiations for expired drugs. Especially in recent years, the centralized procurement of "quantity for price" has further squeezed the price of drugs, realized "free cages for birds", and ensured the basic fund balance.

  The second is the largest number of negotiated drugs and the widest range of treatment fields.

The 96 exclusive drugs transferred in the final negotiation, plus the 23 non-exclusive drugs transferred directly, involved 31 clinical groups, accounting for 86% of all clinical groups, and patients benefited more extensively.

  The third is the first attempt to negotiate a price reduction for the drugs in the catalog, which significantly improves the economy.

Evaluation experts selected 14 exclusive drugs with high prices or costs and a large amount of funds for price reduction negotiations. The annual sales amount of these drugs exceeded 1 billion yuan.

After negotiation, the 14 drugs were successfully negotiated and kept in the catalog, with an average price reduction of 43.46%, which established a clear direction for the drugs in the original catalog to continue to improve their economy.

  The fourth is to support the prevention and control of the new crown epidemic.

In this adjustment, we attach great importance to the protection of drugs related to the treatment of new coronary pneumonia, and include ribavirin injection, Abidol granules and other drugs into the catalog. All drugs listed in the latest version of the national new coronary pneumonia diagnosis and treatment plan have been included in the national medical insurance Catalogue to help prevent and control the epidemic with practical actions.

  Fifth, the newly launched drugs this year will be included in the adjustment scope.

In order to better meet the needs of patients for newly-listed drugs, drugs that were marketed before August 17 this year were included in the adjustment scope. Finally, 16 drugs were included in the catalog, reflecting the orientation of supporting new drugs.

  In general, through this negotiation on the entry of the national medical insurance drug catalogue, the medical insurance fund and the drug expenditure of the insured patients did not increase significantly. Under the premise that the fund safety is generally controllable, the medical insurance drug protection capability and level have been improved.

More importantly, it can further guide pharmaceutical companies to form a reasonable and healthy value trend. Finally, by supporting innovation and value purchase, it can effectively promote the high-quality development of my country's pharmaceutical industry from the perspective of strategic purchase, and promote the deepening of the supply-side reform of the pharmaceutical industry.

  The news pointed out that in the next step, the National Medical Insurance Administration will issue documents with relevant departments to guide local governments to implement the new version of the catalog, strengthen monitoring and scheduling, and urge local governments to do a good job of connection and protection of medications to ensure that the new catalog can benefit the people as soon as possible.